GRCE
Grace Therapeutics, Inc.
Price Chart
Latest Quote
$2.39
+0.13 (+5.75%)
Current Price
| Previous Close | $2.26 |
| Open | $2.24 |
| Day High | $2.47 |
| Day Low | $2.24 |
| Volume | 394,801 |
Stock Information
| Shares Outstanding | 16.27M |
| Cash Equivalents | $16.98M |
| Net Income | $-7.79M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $38.89M |
| EPS (TTM) | $-0.47 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $21.92M |
| Income | $-7.79M |
| Book/sh | $3.99 |
| Cash/sh | $1.04 |
| Employees | 5 |
Financial Ratios
| Quick Ratio | 7.92 |
| Current Ratio | 8.10 |
Returns & Margins
| ROA | -9.99% |
| ROE | -11.94% |
Ownership
| Insider Ownership | 25.73% |
| Institutional Ownership | 26.24% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.37 |
| P/B | 0.60 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $5.93 |
Technical Indicators
| SMA20 | $2.36 |
| SMA50 | $2.63 |
| SMA200 | $3.29 |
| RSI | 43.04 |
| ATR | 0.1443 |
| Shares Float | 13.45M |
| Short Float | 15.33% |
| Short Ratio | 4.80 |
| Volatility | 0.36 |
| Rel Volume | 1.40 |
Performance History
| Week | +8.14% |
| Month | +6.70% |
| Quarter | -46.05% |
| 6 Months | -28.66% |
| YTD | -34.70% |
| Year | -20.33% |
| 3 Years | -30.12% |
| 5 Years | -90.61% |
| 10 Years | -96.37% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $2.39 | 394,900 |
| 2026-06-22 | $2.26 | 260,800 |
| 2026-06-18 | $2.38 | 279,900 |
| 2026-06-17 | $2.22 | 169,300 |
| 2026-06-16 | $2.22 | 210,000 |
| 2026-06-15 | $2.21 | 365,600 |
| 2026-06-12 | $2.20 | 407,000 |
| 2026-06-11 | $2.30 | 223,100 |
| 2026-06-10 | $2.31 | 133,600 |
| 2026-06-09 | $2.33 | 151,600 |
| 2026-06-08 | $2.30 | 165,900 |
| 2026-06-05 | $2.30 | 286,100 |
| 2026-06-04 | $2.39 | 360,800 |
| 2026-06-03 | $2.45 | 185,200 |
| 2026-06-02 | $2.50 | 244,100 |
| 2026-06-01 | $2.69 | 507,300 |
| 2026-05-29 | $2.57 | 418,200 |
| 2026-05-28 | $2.43 | 259,100 |
| 2026-05-27 | $2.33 | 89,100 |
| 2026-05-26 | $2.36 | 525,800 |
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
đ° Latest News
Sector Update: Health Care Stocks Edge Lower Late Afternoon
MT Newswires âĸ 2026-04-23T19:51:01ZWe're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate
Simply Wall St. âĸ 2026-04-04T13:52:14Z
This Grace Therapeutics Insider Increased Their Holding By 12% Last Year
Simply Wall St. âĸ 2025-11-01T14:14:36Z
We Think Grace Therapeutics (NASDAQ:GRCE) Needs To Drive Business Growth Carefully
Simply Wall St. âĸ 2025-09-23T13:55:15Z
Grace Therapeutics, Inc. (NASDAQ:GRCE) Is Expected To Breakeven In The Near Future
Simply Wall St. âĸ 2025-06-24T10:35:35Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Reconciled Cost Of Revenue | - | - | - | - |
| Cost Of Revenue | - | - | - | - |
| Expenses | ||||
| Total Expenses | $11,077,000 | $16,679,000 | $11,367,000 | $18,247,000 |
| Other Income Expense | $899,000 | $3,201,000 | $-4,229,000 | $-33,970,000 |
| Net Non Operating Interest Income Expense | $685,000 | $711,000 | $911,000 | $246,000 |
| Operating Expense | $11,077,000 | $16,679,000 | $11,367,000 | $18,247,000 |
| General And Administrative Expense | $8,665,000 | $7,161,000 | $6,644,000 | $8,076,000 |
| Selling And Marketing Expense | - | - | $194,000 | $136,000 |
| Other Non Operating Income Expenses | - | - | - | - |
| Total Other Finance Cost | - | - | - | - |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-7,793,000 | $-9,568,000 | $-12,853,000 | $-42,429,000 |
| Net Interest Income | $685,000 | $711,000 | $911,000 | $246,000 |
| Interest Income | $685,000 | $711,000 | $911,000 | $246,000 |
| Normalized Income | $-8,531,008 | $-11,966,932 | $-9,151,356 | $-14,695,973 |
| Net Income From Continuing And Discontinued Operation | $-7,793,000 | $-9,568,000 | $-12,853,000 | $-42,429,000 |
| Total Operating Income As Reported | $-11,077,000 | $-16,679,000 | $-12,852,000 | $-52,155,000 |
| Net Income Common Stockholders | $-7,793,000 | $-9,568,000 | $-12,853,000 | $-42,429,000 |
| Net Income | $-7,793,000 | $-9,568,000 | $-12,853,000 | $-42,429,000 |
| Net Income Including Noncontrolling Interests | $-7,793,000 | $-9,568,000 | $-12,853,000 | $-42,429,000 |
| Net Income Continuous Operations | $-7,793,000 | $-9,568,000 | $-12,853,000 | $-42,429,000 |
| Pretax Income | $-9,493,000 | $-12,767,000 | $-14,685,000 | $-51,971,000 |
| Interest Income Non Operating | $685,000 | $711,000 | $911,000 | $246,000 |
| Operating Income | $-11,077,000 | $-16,679,000 | $-11,367,000 | $-18,247,000 |
| Depreciation Amortization Depletion Income Statement | $7,000 | $7,000 | $40,000 | $63,000 |
| Depreciation And Amortization In Income Statement | $7,000 | $7,000 | $40,000 | $63,000 |
| Depreciation Income Statement | $7,000 | $7,000 | $40,000 | $63,000 |
| Special Income Charges | - | $0 | $-1,485,000 | $-33,908,000 |
| Gross Profit | - | - | - | - |
| Per Share | ||||
| Diluted EPS | - | $-0.79 | $-1.35 | $-5.71 |
| Basic EPS | - | $-0.79 | $-1.35 | $-5.71 |
| Other | ||||
| Tax Effect Of Unusual Items | $160,992 | $802,068 | $-527,356 | $-6,236,973 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,969,000 | $-19,873,000 | $-7,098,000 | $15,847,000 |
| Total Unusual Items | $899,000 | $3,201,000 | $-4,229,000 | $-33,970,000 |
| Total Unusual Items Excluding Goodwill | $899,000 | $3,201,000 | $-4,229,000 | $-33,970,000 |
| Reconciled Depreciation | $7,000 | $7,000 | $11,000 | $124,000 |
| EBITDA (Bullshit earnings) | $-11,070,000 | $-16,672,000 | $-11,327,000 | $-18,123,000 |
| EBIT | $-11,077,000 | $-16,679,000 | $-11,367,000 | $-18,247,000 |
| Diluted NI Availto Com Stockholders | $-7,793,000 | $-9,568,000 | $-12,853,000 | $-42,429,000 |
| Tax Provision | $-1,700,000 | $-3,199,000 | $-1,832,000 | $-9,542,000 |
| Gain On Sale Of Security | $899,000 | $3,201,000 | $-2,744,000 | $-62,000 |
| Research And Development | $2,405,000 | $9,511,000 | $4,683,000 | $9,972,000 |
| Selling General And Administration | $8,665,000 | $7,161,000 | $6,644,000 | $8,212,000 |
| Other Gand A | $6,305,000 | $4,616,000 | $4,745,000 | $4,066,000 |
| Salaries And Wages | $2,360,000 | $2,545,000 | $1,899,000 | $4,010,000 |
| Diluted Average Shares | - | $12,087,270 | $9,529,123 | $7,435,472 |
| Basic Average Shares | - | $12,087,270 | $9,529,123 | $7,435,472 |
| Restructuring And Mergern Acquisition | - | $0 | $1,485,000 | $0 |
| Write Off | - | - | $0 | $400,000 |
| Impairment Of Capital Assets | - | - | $0 | $33,508,000 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $14,630,000 | $17,344,000 | $12,477,000 | $18,689,000 |
| Total Assets | $66,654,000 | $71,993,000 | $73,300,000 | $79,123,000 |
| Total Non Current Assets | $49,274,000 | $49,281,000 | $49,290,000 | $49,833,000 |
| Goodwill And Other Intangible Assets | $49,266,000 | $49,266,000 | $49,266,000 | $49,266,000 |
| Other Intangible Assets | $41,128,000 | $41,128,000 | $41,128,000 | $41,128,000 |
| Current Assets | $17,380,000 | $22,712,000 | $24,010,000 | $29,290,000 |
| Prepaid Assets | $383,000 | $453,000 | $283,000 | $598,000 |
| Receivables | $20,000 | $126,000 | $722,000 | $802,000 |
| Accounts Receivable | $20,000 | $126,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $16,977,000 | $22,133,000 | $23,005,000 | $27,890,000 |
| Cash And Cash Equivalents | $16,977,000 | $22,133,000 | $23,005,000 | $27,875,000 |
| Other Receivables | - | $20,000 | $391,000 | $412,000 |
| Taxes Receivable | - | $106,000 | $316,000 | $338,000 |
| Accrued Interest Receivable | - | $0 | $15,000 | $52,000 |
| Assets Held For Sale Current | - | - | - | $0 |
| Cash Financial | - | - | - | $27,875,000 |
| Current Deferred Assets | - | - | - | - |
| Cash Equivalents | - | - | - | - |
| Debt | ||||
| Total Debt | - | - | $0 | $485,000 |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $410,000 |
| Current Debt And Capital Lease Obligation | - | - | - | $75,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,758,000 | $5,383,000 | $11,557,000 | $11,168,000 |
| Total Non Current Liabilities Net Minority Interest | $612,000 | $3,453,000 | $9,873,000 | $7,757,000 |
| Derivative Product Liabilities | $0 | $1,141,000 | $4,359,000 | $0 |
| Non Current Deferred Liabilities | $612,000 | $2,312,000 | $5,514,000 | $7,347,000 |
| Non Current Deferred Taxes Liabilities | $612,000 | $2,312,000 | $5,514,000 | $7,347,000 |
| Current Liabilities | $2,146,000 | $1,930,000 | $1,684,000 | $3,411,000 |
| Payables And Accrued Expenses | $2,146,000 | $1,930,000 | $1,684,000 | $3,336,000 |
| Payables | $1,421,000 | $1,262,000 | $1,508,000 | $2,390,000 |
| Other Payable | $719,000 | $661,000 | $501,000 | $1,148,000 |
| Accounts Payable | $702,000 | $601,000 | $1,007,000 | $1,242,000 |
| Equity | ||||
| Common Stock Equity | $63,896,000 | $66,610,000 | $61,743,000 | $67,955,000 |
| Total Equity Gross Minority Interest | $63,896,000 | $66,610,000 | $61,743,000 | $67,955,000 |
| Stockholders Equity | $63,896,000 | $66,610,000 | $61,743,000 | $67,955,000 |
| Gains Losses Not Affecting Retained Earnings | $-6,038,000 | $-6,038,000 | $-6,038,000 | $-6,038,000 |
| Other Equity Adjustments | $-6,038,000 | $-6,038,000 | $-6,038,000 | $-6,038,000 |
| Retained Earnings | $-228,480,000 | $-220,687,000 | $-211,119,000 | $-198,266,000 |
| Other | ||||
| Ordinary Shares Number | $16,024,026 | $13,718,106 | $9,399,404 | $7,435,471 |
| Share Issued | $16,024,026 | $13,718,106 | $9,399,404 | $7,435,471 |
| Tangible Book Value | $14,630,000 | $17,344,000 | $12,477,000 | $18,689,000 |
| Invested Capital | $63,896,000 | $66,610,000 | $61,743,000 | $67,955,000 |
| Working Capital | $15,234,000 | $20,782,000 | $22,326,000 | $25,879,000 |
| Total Capitalization | $63,896,000 | $66,610,000 | $61,743,000 | $67,955,000 |
| Additional Paid In Capital | $298,413,000 | $293,334,000 | $278,899,000 | $13,965,000 |
| Capital Stock | $1,000 | $1,000 | $1,000 | $258,294,000 |
| Common Stock | $1,000 | $1,000 | $1,000 | $258,294,000 |
| Preferred Stock | $0 | $0 | $0 | - |
| Current Accrued Expenses | $725,000 | $668,000 | $176,000 | $946,000 |
| Goodwill | $8,138,000 | $8,138,000 | $8,138,000 | $8,138,000 |
| Net PPE | $8,000 | $15,000 | $24,000 | $567,000 |
| Accumulated Depreciation | $-14,000 | $-11,000 | $-698,000 | $-609,000 |
| Gross PPE | $22,000 | $26,000 | $722,000 | $1,176,000 |
| Machinery Furniture Equipment | $22,000 | $26,000 | $151,000 | $127,000 |
| Capital Lease Obligations | - | - | $0 | $485,000 |
| Long Term Capital Lease Obligation | - | - | $0 | $410,000 |
| Current Capital Lease Obligation | - | - | $0 | $75,000 |
| Other Properties | - | - | $571,000 | $1,049,000 |
| Other Short Term Investments | - | - | $0 | $15,000 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-8,869,000 | $-14,904,000 | $-12,355,000 | $-15,930,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-8,869,000 | $-14,904,000 | $-12,333,000 | $-15,913,000 |
| Cash Flow From Continuing Operating Activities | $-8,869,000 | $-14,904,000 | $-12,333,000 | $-15,913,000 |
| Operating Gains Losses | $-900,000 | $-3,216,000 | $2,708,000 | $34,000 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $0 | $104,000 | $13,153,000 |
| Cash Flow From Continuing Investing Activities | $0 | $0 | $104,000 | $13,153,000 |
| Capital Expenditure | - | - | $-22,000 | $-17,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $14,999,000 | $7,500,000 | $304,000 |
| Financing Cash Flow | $3,713,000 | $14,032,000 | $7,359,000 | $304,000 |
| Cash Flow From Continuing Financing Activities | $3,713,000 | $14,032,000 | $7,359,000 | $304,000 |
| Net Other Financing Charges | $-327,000 | $-967,000 | $-162,000 | - |
| Net Common Stock Issuance | $0 | $14,999,000 | $7,500,000 | $304,000 |
| Common Stock Issuance | $0 | $14,999,000 | $7,500,000 | $304,000 |
| Other | ||||
| End Cash Position | $16,977,000 | $22,133,000 | $23,005,000 | $27,875,000 |
| Beginning Cash Position | $22,133,000 | $23,005,000 | $27,875,000 | $30,339,000 |
| Changes In Cash | $-5,156,000 | $-872,000 | $-4,870,000 | $-2,456,000 |
| Proceeds From Stock Option Exercised | $4,040,000 | $0 | $21,000 | $0 |
| Net Investment Purchase And Sale | $0 | $0 | $15,000 | $13,170,000 |
| Sale Of Investment | $0 | $15,000 | $6,569,000 | $18,185,000 |
| Purchase Of Investment | $0 | $-15,000 | $-6,554,000 | $-5,015,000 |
| Change In Working Capital | $719,000 | $342,000 | $-1,280,000 | $181,000 |
| Change In Payables And Accrued Expense | $543,000 | $-84,000 | $-1,652,000 | $411,000 |
| Change In Payable | $543,000 | $-84,000 | $-1,652,000 | $411,000 |
| Change In Prepaid Assets | $70,000 | $-170,000 | $315,000 | $72,000 |
| Change In Receivables | $106,000 | $596,000 | $80,000 | $-302,000 |
| Stock Based Compensation | $798,000 | $730,000 | $913,000 | $1,811,000 |
| Deferred Tax | $-1,700,000 | $-3,199,000 | $-1,832,000 | $-9,542,000 |
| Deferred Income Tax | $-1,700,000 | $-3,199,000 | $-1,832,000 | $-9,542,000 |
| Depreciation Amortization Depletion | $7,000 | $7,000 | $11,000 | $124,000 |
| Depreciation And Amortization | $7,000 | $7,000 | $11,000 | $124,000 |
| Depreciation | $7,000 | $7,000 | $11,000 | $124,000 |
| Gain Loss On Investment Securities | $-900,000 | $-3,218,000 | $2,728,000 | $-10,000 |
| Net Income From Continuing Operations | $-7,793,000 | $-9,568,000 | $-12,853,000 | $-42,429,000 |
| Net PPE Purchase And Sale | - | $0 | $89,000 | $-17,000 |
| Sale Of PPE | - | $0 | $111,000 | $0 |
| Purchase Of PPE | - | $0 | $-22,000 | $-17,000 |
| Change In Other Current Assets | - | $0 | $-23,000 | $0 |
| Gain Loss On Sale Of PPE | - | $0 | $-59,000 | $0 |
| Effect Of Exchange Rate Changes | - | - | $0 | $-8,000 |
| Asset Impairment Charge | - | - | $0 | $33,908,000 |
| Net Foreign Currency Exchange Gain Loss | - | - | $0 | $5,000 |
| Amortization Cash Flow | - | - | - | - |
| Amortization Of Intangibles | - | - | - | - |
| Repayment Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
| Other Non Cash Items | - | - | - | - |
Fetched: 2026-06-24